Biotech: Page
-
Permission granted by Versant Ventures
Q&A // Emerging biotechVersant’s Jerel Davis on build-to-buy deals and pharma investment
Build-to-buy arrangements can give pharmaceutical companies an option to acquire a startup’s assets later, as with Novartis’ deal with the Versant-backed Borealis Biosciences.
By Gwendolyn Wu • Aug. 26, 2024 -
Getty Images
Sponsored by AltasciencesHow biotech companies and CROs can better align to accelerate development for the most promising discoveries
CROs are vital in supporting biotech with R&D. How can that relationship go from transactional to partnership?
Aug. 26, 2024 -
Explore the Trendline➔
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
TrendlineCell therapy
The continued emergence of CAR-T therapy has fueled research into next-generation approaches and new applications, such as its use in autoimmune diseases or in reprogramming cells inside the body.
By BioPharma Dive staff -
Permission granted by Menarini Silicon Biosystems
Sponsored by Menarini Silicon BiosystemsA truly comprehensive liquid biopsy approach: DLL3 and the rise of customized CTC and cfDNA/cfRNA analysis with CellSearch® and MenariniSearch
Imagine the power of combining CTCs, cell-free DNA and cell-free RNA.
Aug. 26, 2024 -
Michael M. Santiago via Getty Images
Two antibody startups file for IPOs amid summer slump
Armed with clinical-stage data, Zenas BioPharma and Bicara Therapeutics both fit the profile of biotechs that have successfully pulled off IPOs this year.
By Gwendolyn Wu • Aug. 23, 2024 -
Getty Images
FDA to convene immunotherapy panel; Tome scales back operations
Agency advisers will discuss whether use of Keytruda and Opdivo should be limited in gastric cancer. Elsewhere, a buzzy genetic drug startup is exploring “strategic options.”
By BioPharma Dive staff • Aug. 23, 2024 -
National Institute of Allergy and Infectious Disease. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
Updated COVID shots from Pfizer, Moderna cleared by FDA
Approval of the reformulated mRNA vaccines, which are designed to target the KP.2 virus strain, comes just ahead of the fall and winter seasons.
By Ned Pagliarulo • Aug. 22, 2024 -
Courtesy of Novartis
Versant reimagines its Chinook success with newest startup launch
Borealis Biosciences launches with money from Novartis, which last year bought the biotech’s predecessor for drugs that treat a rare kidney disorder.
By Gwendolyn Wu • Aug. 22, 2024 -
Getty Images
BridgeBio sends rare disease drugs to new company
Backed by $300 million from investors that include Viking Global Investors and Sequoia Capital, GondolaBio will inherit several BridgeBio drug programs.
By Ned Pagliarulo • Aug. 21, 2024 -
Courtesy of BioMarin Pharmaceutical
BioMarin taps Amgen, Roche vets in executive reshuffle
Greg Friberg and James Sabry will take over, respectively, as heads of R&D and business development, less than a year after BioMarin named a new CEO.
By Jacob Bell • Aug. 21, 2024 -
Getty Images
Avidity, Kymera raise fresh funds; Walgreens partners with BARDA
Avidity raised $345 million to advance development of RNA medicines designed to combine the advantages of oligonucleotides and antibodies.
By BioPharma Dive staff • Aug. 20, 2024 -
Getty Images
Zealand, Arrowhead advance obesity drugs; Bluebird narrows guidance
Zealand is using a recent $1 billion equity raise to “accelerate” several would-be weight loss medicines. Meanwhile, Bluebird reworked a loan and Boundless Bio cut jobs only months after an IPO.
By BioPharma Dive staff • Aug. 16, 2024 -
Getty Images
Lykos to cut 75% of staff after FDA rejection of MDMA-based therapy
The layoffs are part of a larger reorganization that will also see the departure of Lykos’ founder, the psychedelics advocate Rick Doblin.
By Jacob Bell • Aug. 15, 2024 -
Courtesy of Grail
Grail to shed 350 workers in restructuring
Less than two months after splitting from Illumina, the liquid biopsy maker is refocusing resources as it pursues an FDA submission for the Galleri multi-cancer early detection test.
By Susan Kelly • Aug. 14, 2024 -
Getty Images
Acelyrin shifts from main drug, lays off staff
The company will no longer develop its medicine izokibep in two immune conditions, prioritizing another treatment it’s developing for thyroid eye disease.
By Ned Pagliarulo • Aug. 13, 2024 -
Sarah Silbiger via Getty Images
Galderma wins FDA approval for skin condition treatment
Nemluvio is now cleared for adults with the chronic itching condition prurigo nodularis, making it a competitor to Sanofi and Regeneron’s Dupixent.
By Ned Pagliarulo • Updated Aug. 13, 2024 -
Getty Images
Lilly opens R&D hub; Ovid and Lexicon lay off staff
Lilly’s new center in Boston will focus on genetic medicine research and provide lab space for startups. Elsewhere, two biotechs cut jobs and two others advanced psychedelic medicines.
By BioPharma Dive staff • Aug. 13, 2024 -
Getty Images
Startup Halda raises $126M to advance new type of targeted cancer therapy
Technology inspired by work at Yale researcher Craig Crews’ labs will be used to target prostate and breast cancer in early clinical trials.
By Jonathan Gardner • Updated Aug. 13, 2024 -
Sarah Silbiger via Getty Images
FDA approves Ascendis drug for rare endocrine condition
The clearance of Yorvipath for hypoparathyroidism was some time coming for Ascendis, which had resubmitted after receiving a rejection last year.
By Ned Pagliarulo • Aug. 12, 2024 -
Getty Images
Emerging biotechWith pharma in ‘catbird seat,’ biotechs get less upfront in drug partnerships
Recent data from J.P. Morgan indicates early-stage startups are getting smaller upfront payments in alliances than a few years ago, a trend industry insiders attribute to weaker leverage in deal talks.
By Gwendolyn Wu • Aug. 9, 2024 -
Getty Images
Merck TIGIT drug fails another trial; Intellia therapy succeeds in HAE study
Merck stopped a Phase 3 TIGIT study for futility. Elsewhere, shares in Cabaletta Bio sank on safety worries and Vertex secured Casgevy reimbursement in England.
By BioPharma Dive staff • Aug. 8, 2024 -
Courtesy of Apellis Pharmaceuticals
Apellis plans FDA filing after drug success in kidney trial
Analysts at Evercore ISI called pegcetacoplan’s data in two kidney conditions a “left-field hit” that compare favorably to results for a Novartis treatment.
By Ned Pagliarulo • Aug. 8, 2024 -
Getty Images
Amgen talks obesity drug ‘differentiation’; Servier brain cancer drug approved by FDA
Executives at Amgen had few updates on their drug MariTide, but defended what they see as the once-monthly shot’s competitive profile.
By BioPharma Dive staff • Aug. 7, 2024 -
Courtesy of Madrigal Pharmaceuticals
Madrigal’s MASH drug launch gets off to a fast start
U.S. sales of the medicine, Rezdiffra, were more than triple analysts’ expectations, encouraging Madrigal to market it in Europe without a partner.
By Ben Fidler • Aug. 7, 2024 -
Courtesy of Roche
Roche licenses Sangamo’s technology for another shot at Alzheimer’s drugs
Through a new deal, Roche has exclusive rights to Sangamo molecules designed to repress the gene that makes “tau,” a protein many scientists view as a main driver of Alzheimer’s.
By Jacob Bell • Aug. 6, 2024 -
Getty Images
Biotech entrepreneur Arie Belldegrun launches new ‘science-first’ credit firm
Symbiotic Capital, which has $600 million in committed capital, aims to make credit a more accessible tool for life sciences companies.
By Delilah Alvarado • Aug. 6, 2024
Previous
